1. Home
  2. SNDL vs TRDA Comparison

SNDL vs TRDA Comparison

Compare SNDL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SNDL Inc.

SNDL

SNDL Inc.

HOLD

Current Price

$1.60

Market Cap

432.6M

Sector

Health Care

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$11.02

Market Cap

404.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDL
TRDA
Founded
2006
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
432.6M
404.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
SNDL
TRDA
Price
$1.60
$11.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$20.00
AVG Volume (30 Days)
1.9M
229.0K
Earning Date
03-17-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$683,170,243.00
$61,520,000.00
Revenue This Year
$5.48
N/A
Revenue Next Year
$3.41
$3.14
P/E Ratio
N/A
N/A
Revenue Growth
4.43
N/A
52 Week Low
$1.15
$4.93
52 Week High
$2.89
$14.27

Technical Indicators

Market Signals
Indicator
SNDL
TRDA
Relative Strength Index (RSI) 41.48 55.09
Support Level $1.45 $10.34
Resistance Level $1.67 $12.18
Average True Range (ATR) 0.07 0.75
MACD 0.00 0.03
Stochastic Oscillator 60.00 59.65

Price Performance

Historical Comparison
SNDL
TRDA

About SNDL SNDL Inc.

SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: